Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Teste de Bevacizumabe, Erlotinibe e Atezolizumabe para Câncer de Rim em Estágio Avançado

27 de outubro de 2026 atualizado por: National Cancer Institute (NCI)

Um Estudo de Fase 2 de Bevacizumabe, Erlotinibe e Atezolizumabe em Indivíduos com Leiomiomatose Hereditária Avançada e Câncer de Células Renais (HLRCC) Associado ou Câncer Esporádico de Células Renais Papilares

This phase II trial studies the effects of combination therapy with bevacizumab, erlotinib, and atezolizumab in treating patients with hereditary leiomyomatosis and kidney cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Bevacizumab is in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumors. This may slow the growth and spread of tumors. Erlotinib is in a class of medications called kinase inhibitors. It works by blocking the action of a protein called EGFR that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Combination therapy with bevacizumab, erlotinib, and atezolizumab may stabilize or shrink advanced hereditary leiomyomatosis and kidney cancer.

Visão geral do estudo

Descrição detalhada

PRIMARY OBJECTIVE:

I. To assess the complete response (CR) rate according to standard Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) in patients with 1) advanced renal cell cancer (RCC) associated with hereditary leiomyomatosis and renal cell cancer (HLRCC) and 2) advanced sporadic/non-HLRCC papillary renal cell cancer treated with a combination of bevacizumab, erlotinib, and atezolizumab.

SECONDARY OBJECTIVES:

I. To determine the safety and tolerability of the combination of bevacizumab, erlotinib, and atezolizumab.

II. To determine the objective response rate (ORR) as complete response (CR) + partial response (PR).

III. To determine disease control rate (DCR) - confirmed response, or stable disease (SD) lasting for at least 6 months.

IV. To assess progression-free survival time (PFS) according to RECIST 1.1. V. To assess overall survival (OS). VI. To assess the duration of response. VII. To assess response to treatment using immune-modified Response Evaluation Criteria in Solid Tumors (iRECIST).

EXPLORATORY OBJECTIVES:

I. To evaluate immunologic modulation associated with the administered treatment regimen, including:

Ia. Peripheral immune subset analysis before and on treatment; Ib. Evaluation of relevant soluble factors before and on treatment. (e.g., cytokine profiles); Ic. Tumor tissue immune infiltration cells before and after treatment (immune microenvironment, CD8/CD4/CD3 cells, T-cell receptor clonality); Id. Evaluation of tissue PDL1/PD1 expression and their correlation with outcome.

II. To assess specific genomic alterations (including fumarate hydratase [FH], NRF2 pathway) and determine if there is a correlation with clinical outcomes.

OUTLINE:

Patients receive bevacizumab intravenously (IV) over 30-90 minutes and atezolizumab IV over 30-60 minutes on day 1 of each cycle. Patients also receive erlotinib orally (PO) once daily (QD) on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT) with or without contrast and magnetic resonance imaging (MRI) throughout the trial. Patients undergo collection of blood throughout the trial, and may undergo a biopsy during screening, as well as a brain MRI/CT scan with contrast, bone scan, and/or F-18 sodium fluoride positron emission tomography (PET) scan as clinically indicated.

After completion of study treatment, patients are followed up every 6 months.

Tipo de estudo

Intervencional

Inscrição (Estimado)

65

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • California
      • La Jolla, California, Estados Unidos, 92093
        • Suspenso
        • UC San Diego Moores Cancer Center
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30322
        • Recrutamento
        • Emory University Hospital/Winship Cancer Institute
        • Contato:
          • Site Public Contact
          • Número de telefone: 404-778-1868
        • Investigador principal:
          • Mehmet A. Bilen
      • Atlanta, Georgia, Estados Unidos, 30308
        • Recrutamento
        • Emory University Hospital Midtown
        • Contato:
          • Site Public Contact
          • Número de telefone: 888-946-7447
        • Investigador principal:
          • Mehmet A. Bilen
      • Atlanta, Georgia, Estados Unidos, 30342
        • Recrutamento
        • Emory Saint Joseph's Hospital
        • Contato:
          • Site Public Contact
          • Número de telefone: 404-851-7115
        • Investigador principal:
          • Mehmet A. Bilen
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60611
        • Suspenso
        • Northwestern University
    • Maryland
      • Bethesda, Maryland, Estados Unidos, 20892
        • Recrutamento
        • NCI - Center for Cancer Research
        • Investigador principal:
          • Ramaprasad Srinivasan
        • Contato:
          • Site Public Contact
          • Número de telefone: 800-411-1222
      • Bethesda, Maryland, Estados Unidos, 20892
        • Suspenso
        • National Institutes of Health Clinical Center
    • New Jersey
      • New Brunswick, New Jersey, Estados Unidos, 08903
        • Suspenso
        • Rutgers Cancer Institute of New Jersey
    • New York
      • Mineola, New York, Estados Unidos, 11501
        • Ativo, não recrutando
        • NYU Langone Hospital - Long Island
      • New York, New York, Estados Unidos, 10016
        • Ativo, não recrutando
        • Laura and Isaac Perlmutter Cancer Center at NYU Langone
    • Ohio
      • Columbus, Ohio, Estados Unidos, 43210
        • Recrutamento
        • Ohio State University Comprehensive Cancer Center
        • Contato:
        • Investigador principal:
          • Yuanquan Yang
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Estados Unidos, 15232
        • Suspenso
        • UPMC Hillman Cancer Center
    • Texas
      • Houston, Texas, Estados Unidos, 77030
        • Recrutamento
        • UT MD Anderson Cancer Center
        • Contato:
        • Investigador principal:
          • Pavlos Msaouel

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

12 anos e mais velhos (Filho, Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Patients must have:

    • A diagnosis of HLRCC with a histologic or cytologic confirmation of RCC consistent with this diagnosis (Cohort 1) OR
    • Cytologically or histologically confirmed sporadic/non-HLRCC papillary renal cell carcinoma (presence of papillary component) (Cohort 2)
  • Patients must have advanced RCC with measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm (>= 2 cm) by chest x-ray or as >= 10 mm (>= 1 cm) with CT scan, MRI, or calipers by clinical exam. To be considered pathologically enlarged and measurable, a lymph node must be >= 15 mm (>= 1.5 cm) in short axis

  • Patients must have received no more than two prior regimens targeting the VEGF pathway and no prior bevacizumab therapy in the metastatic/advanced setting. No prior treatment with PD-1 or PD-L1 inhibitors in the metastatic/advanced setting. No prior therapy is required for eligibility

  • Age >= 12 years

  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)

  • Absolute neutrophil count >= 1,000/mcL

  • Platelets >= 100,000/mcL

  • Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (< 3 x upper limit of reference range in patients with known/suspected Gilbert's disease)

  • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN (or =< 5 x upper limit of reference range if considered to be related to liver or bone metastases by the principal investigator [PI])

  • Alkaline phosphatase =< 2.5 x institutional ULN (or =< 5 x upper limit of reference range if considered to be related to liver or bone metastases by the PI)

    • Note: For pediatric patients (< 18 years of age), ULN for alkaline phosphatase will be defined as 390 IU/L for males and 320 IU/L for females
  • Glomerular filtration rate (GFR) >= 30 mL/min/1.73 m^2

    • Note: For pediatric patients (< 18 years of age) the following creatinine thresholds will be utilized. Patients with a creatinine that exceeds this threshold will require further testing with a confirmation of GFR >= 40 as determined by either 24-hour urine collection or with radioisotope based nuclear medicine evaluation

    • Age: 12 to < 13 years; Maximum serum creatinine (mg/dL): 1.2 (male); 1.2 (female)

    • Age: 13 to < 16 years; Maximum serum creatinine (mg/dL): 1.5 (male); 1.4 (female)

    • Age: 16 to < 18 years; Maximum serum creatinine (mg/dL): 1.7 (male); 1.4 (female)

      • The threshold creatinine values in this table were derived from the Schwartz formula for estimating GFR, utilizing child length and stature data published by the Centers for Disease Control and Prevention (CDC)
  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with an undetectable viral load within 6 months are eligible for this trial

  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated

  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load

  • Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression/recurrence for >= 3 months and the patient no longer requires more than a physiologic dose of steroids

  • Patients does not have a prior or concurrent invasive malignancy; patients are eligible if a prior or concurrent invasive malignancy exists, but the natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen

  • Patients with a known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better

  • The effects of study drugs on the developing human fetus are unknown. For this reason, all women and men of childbearing potential must agree to use adequate contraception (including but not limited to abstinence, barrier methods, hormonal contraceptives [birth control pills, injections, or implants], intrauterine device [IUD], tubal ligation, vasectomy) prior to study entry and for 6 months after completion of study therapy. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, and 6 months after completion of study drugs administration

  • Subjects must provide archival tissue block or unstained tumor tissue or be willing to undergo biopsy to collect samples for retrospective central pathology review

  • The ability of subject or parent/guardian to understand and the willingness to sign a written informed consent document or subjects with impaired decision making capacity (IDMC) if they are represented by a legally authorized representative (LAR)

Exclusion Criteria:

  • Any prior systemic therapy to treat the patient's kidney cancer within 4 weeks or, if known, 5 half-lives of the prior agent (whichever is shorter) prior to cycle 1 day 1

  • Other prior therapies for kidney cancer: Radiotherapy < 2 weeks prior to cycle 1, day 1

  • Major surgical procedure < 28 days before cycle 1, day 1. Surgical wounds must be healed prior to starting therapy

  • Patients who have not recovered from adverse events due to prior systemic anti-cancer therapy (i.e., have residual toxicities > grade 1 of the Common Terminology Criteria for Adverse Events [CTCAE] version [v]5, pre-treatment baseline or to a level permitted under other sections of inclusion/exclusion criteria) with the exception of alopecia or electrolyte abnormalities that can be corrected to =< grade 1 prior to treatment initiation

  • Treatment with any other investigational agent within 4 weeks prior to cycle 1, day 1

  • Treatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]-alpha or interleukin [IL]-2) within 6 weeks prior to cycle 1, day 1

  • Treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1

    • Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea or for purposes of pre-medication prior to radiology studies) may be enrolled
    • The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed
  • Hypercalcemia > grade 1 of the CTCAE v5 that is not corrected prior to treatment initiation

  • Patients taking bisphosphonate therapy for symptomatic hypercalcemia. Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed

  • History of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis

    • Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible

    • Patients with controlled type 1 diabetes mellitus on a stable insulin regimen may be eligible

    • Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:

      • Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations
      • Rash must cover less than 10% of body surface area (BSA)
      • The disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, fluocinolone 0.01%, desonide 0.05%, alclometasone dipropionate 0.05%)
      • No acute exacerbations of the underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
  • History of idiopathic pulmonary fibrosis, pneumonitis (including drug-induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis. History of radiation pneumonitis in the radiation field (fibrosis) is permitted

  • Patients with untreated latent or active tuberculosis (TB) are excluded

  • Severe infections within 4 weeks prior to cycle 1, day 1, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia

  • Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab

    • NOTE: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines and are not allowed. Influenza vaccination should be given during influenza season only (approximately October to March)
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring intravenous antibiotics, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

  • Poorly controlled hypertension with at least 2 occasions of elevated blood pressure separated by a 24-hour periodd within a week before treatment initiation, despite optimal medical management. (Adults: resting systolic blood pressure greater than 140 mmHg or diastolic blood pressure greater than 90 mmHg. Pediatric [< 18 years old]: Blood pressure [BP] >= the 95th percentile for age, height, and sex). History of hypertensive crisis or hypertensive encephalopathy

  • Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation

  • History of anaphylactic or severe allergic reactions attributed to compounds of similar chemical or biologic composition to the study agents

  • Patients with myocardial infarction, gastrointestinal (GI) perforation/fistula, intraabdominal abscess, or cerebrovascular accidents within 6 months before cycle 1, day 1

  • Documented baseline proteinuria > 1000 mg/day on 24-hour urine collection. Only patients with 1+ or greater proteinuria on urinalysis (UA) and a spot urine protein:creatinine ratio of > 0.5 will undergo a 24-hour urine collection for quantitation of proteinuria

  • Pregnant women are excluded from this study because study drugs may have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with study drugs, breastfeeding should be discontinued if the mother is treated with study drugs

  • Serious, non-healing wound or ulcer; bone fracture within 3 months prior to treatment initiation

  • Concomitant therapy with systemic medications or herbal supplements that are known strong inhibitors or inducers of CYP450 3A4, or strong CYP1A2 inducers. To determine the impact of a concomitant drug on CYP enzymes see the FDA-approved product labeling and/or tertiary compendia (e.g., Inhibitors and Inducers of Cytochrome P450 Enzymes)

  • Patients who use tobacco or nicotine products and cannot stop their use of these products for the duration of study treatment

  • Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months prior to cycle 1, day 1

  • History of or active hemoptysis within 1 month prior to cycle 1 day 1

  • History of grade >= 4 venous thromboembolism

  • History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (i.e., in the absence of therapeutic anticoagulation)

  • Current or recent (< 10 days prior to initiation of study treatment) use of aspirin (> 325 mg/day), or clopidogrel (> 75 mg/day)

    • Note: The use of full-dose oral or parenteral anticoagulants for therapeutic purpose is permitted as long as the International Normalized Ratio (INR) and/or a partial thromboplastin time (PTT) is within therapeutic limits (according to institution standards) within 7 days prior to initiation of study treatment and the patient has been on a stable dose of anticoagulants for >= 2 weeks prior to initiation of study treatment. Prophylactic use of anticoagulants is allowed. However, the use of direct oral anticoagulant therapies such as dabigatran (Pradaxa [registered trademark]) and rivaroxaban (Xarelto [registered trademark]) may be used per PI discretion

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Treatment (bevacizumab, atezolizumab, erlotinib)

Patients receive bevacizumab IV over 30-90 minutes and atezolizumab IV over 30-60 minutes on day 1 of each cycle. Patients also receive erlotinib PO QD on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT with or without contrast and MRI throughout the trial. Patients undergo collection of blood throughout the trial, and may undergo a biopsy during screening, as well as a brain MRI/CT scan with contrast, bone scan, and/or F-18 sodium fluoride PET scan as clinically indicated.

Given IV

Outros nomes:
  • AvastinName
  • ABP 215
  • Anti-VEGF
  • Anticorpo Monoclonal Humanizado Anti-VEGF
  • Anticorpo Monoclonal Anti-VEGF SIBP04
  • Anti-VEGF rhuMAb
  • Bevacizumabe awwb
  • Bevacizumabe Biossimilar ABP 215
  • Bevacizumabe Biossimilar BEVZ92
  • Bevacizumabe Biossimilar BI 695502
  • Bevacizumabe Biossimilar CBT 124
  • Bevacizumabe Biossimilar CT-P16
  • Bevacizumabe Biossimilar FKB238
  • Bevacizumabe Biossimilar GB-222
  • Bevacizumabe Biossimilar HD204
  • Bevacizumabe Biossimilar HLX04
  • Bevacizumabe Biossimilar IBI305
  • Bevacizumabe Biossimilar LY01008
  • Bevacizumabe Biossimilar MIL60
  • Bevacizumabe Biossimilar Mvasi
  • Bevacizumabe Biossimilar MYL-1402O
  • Bevacizumabe Biossimilar QL 1101
  • Bevacizumabe Biossimilar RPH-001
  • Bevacizumabe Biossimilar SCT501
  • Bevacizumabe Biossimilar Zirabev
  • Bevacizumabe-awwb
  • Bevacizumabe-bvzr
  • BP102
  • BP102 Biossimilar
  • HD204
  • Imunoglobulina G1 (fator de crescimento endotelial vascular anti-humano monoclonal de cadeia gama rhuMab-VEGF humano-camundongo), dissulfeto com cadeia leve rhuMab-VEGF monoclonal humano-camundongo, dímero
  • Mvasi
  • MYL-1402O
  • Anticorpo Monoclonal Anti-VEGF Humanizado Recombinante
  • rhuMab-VEGF
  • SCT501
  • SIBP 04
  • SIBP-04
  • SIBP04
  • Zirabev
  • Avegra
  • QL1101
  • IBI305
  • Byvasda
  • Bevacizumabe Biossimilar QL1101
  • BAT1706
  • BAT 1706
  • BAT-1706
  • Biossimilar BAT1706
  • Bevacizumabe Biossimilar BAT1706
  • Bevacizumabe-adcd
  • CT-P16
  • Vegzelma
  • Alymsys
  • ABP-215
  • ABP215
  • Aybintio
  • Bevacizumabe-aybi
  • Bevacizumabe-equi
  • Bevacizumabe-maly
  • Bevacizumabe-onbe
  • CT P16
  • CTP16
  • Equidacente
  • Onbevzi
  • Avzivi
  • Bevacizumabe Biossimilar MB02
  • Bevacizumabe-tnjn
  • FKB 238
  • FKB-238
  • FKB238
  • MB 02
  • MB-02
  • MB02
  • Oyavas
  • PF 06439535
  • PF-06439535
  • PF06439535
  • Bevacizumab-aveg
  • Bevacizumab-byva
  • Bevacizumab-nwgd
  • Jobevne
  • IBI 305
  • IBI-305

Undergo MRI

Outros nomes:
  • Ressonância magnética
  • Varredura de imagem por ressonância magnética
  • Imagem Médica, Ressonância Magnética / Ressonância Magnética Nuclear
  • SENHOR
  • Exame de ressonância magnética
  • Imagem NMR
  • Ressonância Magnética Nuclear
  • Ressonância Magnética (MRI)
  • ressonância magnética
  • Ressonância magnética (procedimento)
  • Ressonâncias magnéticas
  • RM estrutural

Undergo biopsy

Outros nomes:
  • Bx
  • TIPO DE BIÓPSIA_TIPO
  • Biópsia

Undergo PET

Outros nomes:
  • Imagem Médica, Tomografia por Emissão de Pósitrons
  • BICHO DE ESTIMAÇÃO
  • PET scan
  • Tomografia por emissão de pósitrons
  • PT
  • Tomografia por emissão de pósitrons (procedimento)

Given PO

Undergo bone scan

Outros nomes:
  • Cintilografia Óssea

Undergo CT with contrast

Outros nomes:
  • Tomografia computadorizada com contraste aprimorado
  • TC DE CONTRASTE AUMENTADA
  • Tomografia computadorizada com contraste
  • Tomografia Computadorizada Com Contraste
  • TC com contraste

Given PO

Outros nomes:
  • Tecentriq
  • MPDL3280A
  • RO5541267
  • RG7446
  • MPDL 3280A
  • MPDL 328OA
  • MPDL-3280A
  • MPDL328OA
  • RG-7446
  • RO-5541267

Undergo blood collection

Outros nomes:
  • Coleta de Amostras Biológicas
  • Bioespécime coletado
  • Coleta de amostras

Undergo CT without contrast

Outros nomes:
  • TC
  • GATO
  • Tomografia
  • Tomografia Axial Computadorizada
  • Tomografia computadorizada
  • tomografia
  • Tomografia axial computadorizada (procedimento)
  • Tomografia computadorizada (TC)
  • Diagnóstico Cat Scan
  • Tipo de serviço de varredura de gato diagnóstico

Given F-18 sodium fluoride

Outros nomes:
  • 18 F-NaF
  • F-18 NaF
  • Flúor F 18 Fluoreto de Sódio
  • NaF F18
  • Fluoreto de Sódio F18

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Incidence of adverse events
Prazo: Up to 28 days after treatment

To determine the safety and tolerability of the combination of bevacizumab, erlotinib, and atezolizumab, the fraction of patients with a dose-limiting toxicity will be reported, along with the maximum grade and type of toxicity for each type noted. Note: In addition to adverse events in the entire study population, pediatric toxicities will also be reported and analyzed separately.

Up to 28 days after treatment
Objective response rate
Prazo: Up to 2 years from study enrollment

Defined as complete response (CR) + partial response (PR), the fraction with a response (CR+PR) will be reported separately by cohort, along with a 95% confidence interval.

Up to 2 years from study enrollment
Disease control rate
Prazo: Up to 2 years from study enrollment

Will be reported for patients with confirmed response, or stable disease (SD) lasting for at least 6 months. Will be reported separately by cohort, along with a 95% confidence interval.

Up to 2 years from study enrollment
Progression-free survival time (PFS)
Prazo: Time from study treatment initiation until disease progression or death, assessed up to 2 years from study enrollment

Assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, PFS will be determined using the Kaplan-Meier method, and the curves presented along with a 95% confidence interval on the median PFS, separately by cohort.

Time from study treatment initiation until disease progression or death, assessed up to 2 years from study enrollment
Overall survival (OS)
Prazo: From study treatment initiation until death from any cause, assessed up to 2 years from study enrollment

The Kaplan-Meier method will be used and the curves presented along with a 95% confidence interval on the median OS, separately by cohort.

From study treatment initiation until death from any cause, assessed up to 2 years from study enrollment
Duration of response (DOR)
Prazo: Length of time without disease progression or recurrence, up to 2 years from study enrollment

The Kaplan-Meier method will be used and the curves presented along with a 95% confidence interval on the median DOR, separately by cohort.

Length of time without disease progression or recurrence, up to 2 years from study enrollment
Response to treatment
Prazo: Assessed up to 2 years from study enrollment

Response to treatment using immune-modified Response Evaluation Criteria in Solid Tumors (iRECIST), the fraction with a response (CR+PR) according to iRECIST will be reported separately by cohort, along with a 95% confidence interval.

Assessed up to 2 years from study enrollment

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Ramaprasad Srinivasan, National Cancer Institute LAO

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

10 de junho de 2022

Conclusão Primária (Estimado)

31 de dezembro de 2027

Conclusão do estudo (Estimado)

31 de dezembro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

28 de julho de 2021

Enviado pela primeira vez que atendeu aos critérios de CQ

28 de julho de 2021

Primeira postagem (Real)

29 de julho de 2021

Atualizações de registro de estudo

Última Atualização Postada (Real)

28 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

27 de outubro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • NCI-2021-07744
  • 10466 (Outro identificador: CTEP)
  • NCI-2021-07744 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
  • 22-C-0004
  • 10466 (Outro identificador: National Cancer Institute LAO)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever